The O
relationship O
between O
interleukin-6 O
and O
functional O
connectivity O
in O
methamphetamine O
users O
Methamphetamine O
( O
MA O
) O
causes O
an O
increase O
in O
pro-inflammatory O
cytokines O
in O
animal O
models O
and O
in O
humans O
. O

Resulting O
activation O
of O
microglia O
and O
neuro-inflammation O
could O
, O
via O
effects O
on O
reward O
networks O
, O
mediate O
behavioral O
characteristics O
of O
addiction O
. O

We O
examined O
the O
relationship O
between O
interleukin-6 O
( O
IL-6 O
) O
and O
corticolimbic O
and O
striatolimbic O
resting-state O
functional O
connectivity O
( O
RSFC O
) O
. O

Thirty O
adults O
diagnosed O
with O
MA O
dependence O
and O
20 O
control O
subjects O
underwent O
a O
resting-state O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
scan O
and O
gave O
a O
blood O
sample O
for O
determination O
of O
plasma O
IL-6 O
levels O
. O

Seed-based O
RSFC O
analyses O
were O
performed O
to O
examine O
the O
interactive O
effect O
of O
group O
and O
IL-6 O
on O
ventral O
striatal O
and O
prefrontal O
connectivity O
. O

Within O
the O
MA O
group O
, O
IL-6 O
levels O
were O
positively O
related O
to O
striatolimbic O
RSFC O
but O
negatively O
related O
to O
corticostriatal O
RSFC O
. O

Our O
findings O
with O
IL-6 O
support O
the O
idea O
that O
inflammation O
may O
at O
least O
partly O
mediate O
the O
link O
among O
MA O
use O
disorder O
, O
RSFC O
, O
and O
behavior O
, O
possibly O
via O
effects O
on O
mesolimbic O
and O
mesocortical O
dopaminergic O
systems O
. O

2 O
. O

Materials O
and O
methods O
2.1 O
. O

Participants O
Thirty O
volunteers O
diagnosed O
with O
MA O
dependence O
and O
20 O
healthy O
controls O
provided O
written O
informed O
consent O
, O
as O
approved O
by O
the O
Veterans O
Affairs O
Portland O
Health O
Care O
System O
( O
VAPORHCS O
) O
and O
Oregon O
Health O
& O
Science O
University O
Institutional O
Review O
Boards O
( O
IRBs O
) O
. O

The O
work O
was O
carried O
out O
in O
accordance O
with O
The O
Code O
of O
Ethics O
of O
the O
World O
Medical O
Association O
( O
Declaration O
of O
Helsinki O
) O
. O

Participants O
in O
the O
MA O
group O
were O
recruited O
through O
word O
of O
mouth O
, O
IRB-approved O
advertisements O
, O
and O
referrals O
from O
VAPORHCS O
, O
the O
community O
, O
and O
from O
addiction O
treatment O
centers O
. O

Control O
participants O
were O
recruited O
by O
advertisement O
from O
the O
general O
public O
and O
from O
friends O
and O
families O
of O
those O
who O
attended O
the O
clinics O
associated O
with O
the O
study O
. O

Exclusion O
criteria O
for O
both O
groups O
, O
determined O
by O
medical O
history O
and O
laboratory O
blood O
tests O
were O
: O
systemic O
, O
neurological O
, O
cardiovascular O
, O
or O
pulmonary O
disease O
, O
head O
trauma O
with O
loss O
of O
consciousness O
, O
magnetic O
resonance O
imaging O
( O
MRI O
) O
contraindications O
, O
use O
of O
medications O
known O
to O
have O
dopaminergic O
mechanisms O
( O
e.g. O
, O
antipsychotics O
, O
antidepressants O
, O
antiparkinsonian O
agents O
) O
, O
sedative-hypnotics O
( O
barbiturates O
, O
benzodiazepines O
, O
zolpidem O
) O
or O
anticholinergics O
. O

Past O
or O
Current O
Axis O
I O
diagnoses O
, O
other O
than O
depression O
, O
posttraumatic O
stress O
disorder O
or O
nicotine O
dependence O
for O
either O
group O
, O
assessed O
with O
the O
the O
Mini-International O
Neuropsychiatric O
Interview O
( O
M.I.N.I O
. O

) O
, O
and O
alcohol O
use O
> O
7 O
standard O
drinks O
per O
week O
for O
women O
and O
> O
14 O
drinks O
per O
week O
for O
men O
were O
exclusionary O
. O

For O
inclusion O
in O
the O
MA O
group O
, O
participants O
met O
DSM-IV O
criteria O
for O
MA O
dependence O
and O
had O
been O
abstinent O
from O
MA O
for O
> O
1 O
month O
and O
< O
6 O
months O
( O
Note O
: O
Although O
the O
currently O
accepted O
terminology O
is O
methamphetamine O
use O
disorder O
, O
as O
per O
the O
DSM-5 O
, O
the O
diagnostic O
category O
was O
previously O
termed O
MA O
dependence O
, O
and O
this O
term O
is O
used O
when O
referring O
to O
the O
research O
participants O
described O
in O
this O
paper O
) O
. O

Urine O
testing O
on O
day O
of O
MRI O
scan O
verified O
abstinence O
from O
cocaine O
, O
methamphetamine O
, O
benzodiazepines O
, O
and O
opiates O
. O

2.2 O
. O

Blood O
sample O
collection O
and O
processing O
Blood O
was O
drawn O
from O
non-fasting O
participants O
at O
rest O
by O
one-time O
venipuncture O
. O

Samples O
were O
collected O
in O
cell O
preparation O
tubes O
( O
BD O
Vacutainer O
Systems O
, O
Franklin O
Lakes O
, O
NJ O
, O
USA O
) O
containing O
1 O
mL O
of O
0.1M O
sodium O
citrate O
solution O
. O

The O
blood O
was O
then O
centrifuged O
at O
1500 O
RCF O
for O
20 O
minutes O
at O
room O
temperature O
( O
22–25° O
C O
) O
. O

Plasma O
was O
separated O
, O
collected O
and O
immediately O
aliquoted O
in O
polypropylene O
tubes O
( O
Phenix O
Research O
Products O
, O
Hayward O
, O
CA O
, O
USA O
) O
and O
frozen O
at O
−80° O
C O
until O
assayed O
. O

Every O
effort O
was O
made O
to O
collect O
samples O
between O
11 O
AM O
and O
1 O
PM O
( O
average O
collection O
time O
was O
11:36 O
AM O
) O
; O
mean O
blood O
collection O
times O
by O
study O
group O
were O
as O
follows O
: O
Control O
group O
= O
11:28 O
AM O
and O
MA O
group O
= O
12:05 O
PM O
. O

2.3 O
. O

Multiplex O
immunoassay O
Human O
plasma O
samples O
were O
analyzed O
in O
duplicate O
using O
a O
customized O
, O
high-sensitivity O
multiplex O
polystyrene O
bead-based O
immunoassay O
[ O
Luminex O
Performance O
Assay O
( O
cat O
. O

no O
. O

FCST09-03 O
) O
; O
R O
& O
D O
Systems O
, O
Minneapolis O
, O
MN O
, O
USA O
] O
to O
measure O
peripheral O
immune O
biomarkers O
associated O
with O
inflammation O
, O
specifically O
IL-6 O
and O
IL-1β O
, O
and O
the O
anti-inflammatory O
cytokine O
, O
IL-10 O
. O

The O
manufacturer-reported O
lower O
detection O
limits O
were O
0.31 O
pg/ml O
for O
IL-6 O
, O
0.18 O
pg/ml O
for O
IL-1β O
, O
and O
0.24 O
pg/ml O
for O
IL-10 O
, O
but O
for O
a O
number O
of O
samples O
we O
were O
able O
to O
estimate O
values O
for O
samples O
below O
these O
limits O
. O

Our O
assay O
detection O
limits O
were O
0.06 O
– O
3,719 O
pg/ml O
for O
IL-6 O
, O
0.04 O
– O
1,612 O
pg/ml O
for O
IL-1β O
, O
and O
0.09 O
– O
2,488 O
pg/ml O
for O
IL-10 O
. O

In O
order O
to O
assess O
the O
reliability O
of O
the O
cytokine O
measurements O
, O
we O
calculated O
the O
intra- O
and O
inter-assay O
coefficients O
of O
variations O
( O
CVs O
) O
as O
indices O
of O
within- O
and O
between-assay O
precision O
, O
respectively O
. O

The O
average O
intra-assay O
% O
CVs O
for O
the O
cytokine O
measures O
were O
8.8 O
% O
for O
IL-6 O
, O
11.4 O
% O
for O
IL-1β O
, O
and O
9.9 O
% O
for O
IL-10 O
, O
which O
are O
comparable O
to O
, O
or O
lower O
than O
, O
similar O
multiplexed O
cytokine O
analysis O
. O

The O
inter-assay O
% O
CVs O
( O
indices O
of O
plate-to-plate O
consistency O
) O
were O
calculated O
for O
low O
and O
high O
control O
samples O
with O
known O
cytokine O
concentrations O
. O

The O
average O
of O
the O
low O
and O
high O
% O
CVs O
were O
14.5 O
% O
for O
IL-6 O
, O
27.0 O
% O
for O
IL-1β O
, O
and O
8.2 O
% O
for O
IL-10 O
. O

This O
variation O
is O
comparable O
to O
previously O
reported O
inter-assay O
CVs O
using O
this O
method O
. O

2.4 O
. O

MRI O
imaging O
acquisition O
Imaging O
was O
performed O
on O
a O
3 O
Tesla O
Siemens O
TIM O
Trio O
MRI O
scanner O
. O

A O
localizer O
scan O
was O
acquired O
in O
order O
to O
guide O
slice O
alignment O
during O
anatomical O
and O
functional O
scans O
. O

A O
T2 O
* O
- O
weighted O
echo-planar O
image O
( O
EPI O
) O
was O
acquired O
( O
24 O
slices O
, O
4 O
mm O
thick O
, O
gap O
width O
= O
1 O
mm O
, O
TR/TE/α O
= O
2,000 O
ms/40 O
ms/80° O
, O
matrix O
= O
128 O
× O
128 O
, O
FOV O
= O
240 O
mm2 O
, O
170 O
volumes O
, O
in-plane O
pixel O
size O
of O
1.875 O
mm2 O
) O
while O
subjects O
stared O
at O
a O
white O
cross O
on O
a O
black O
screen O
. O

One O
high-resolution O
T1-weighted O
anatomical O
magnetically O
prepared O
rapid O
acquisition O
gradient O
echo O
( O
MPRAGE O
; O
144 O
slices O
1 O
mm O
thick O
, O
TR/TE/TI/α O
= O
2,300 O
ms/4.38 O
ms/1,200 O
ms/12° O
, O
FOV O
= O
208 O
× O
256 O
mm2 O
) O
was O
acquired O
for O
co-registration O
with O
functional O
images O
and O
statistical O
overlay O
. O

2.5 O
. O

Resting-state O
fMRI O
analysis O
Three O
participants O
in O
the O
MA O
group O
were O
excluded O
for O
incomplete O
scan O
acquisition O
due O
to O
technical O
difficulties O
. O

On O
the O
remaining O
subject O
data O
, O
image O
analysis O
was O
performed O
using O
FSL O
5.0.2.1 O
( O
www.fmrib.ox.ac.uk/fsl O
) O
. O

Images O
were O
realigned O
to O
compensate O
for O
motion O
, O
and O
high-pass O
temporal O
filtering O
( O
100 O
s O
) O
was O
applied O
. O

Data O
were O
skull-stripped O
and O
spatially O
smoothed O
( O
5-mm O
FWHM O
Gaussian O
kernel O
) O
. O

Images O
were O
further O
pre-processed O
to O
include O
additional O
nuisance O
regressors O
: O
average O
signal O
of O
cerebrospinal O
fluid O
, O
average O
signal O
from O
white-matter O
, O
and O
two O
metrics O
of O
motion-related O
artifact O
, O
specifically O
motion O
scrubbing O
with O
frame-wise O
displacement O
and O
a O
combination O
of O
the O
temporal O
derivative O
of O
the O
time O
series O
and O
root-mean-squared O
variance O
over O
all O
voxels O
. O

Global O
signal O
regression O
was O
not O
applied O
. O

The O
EPI O
images O
were O
registered O
to O
the O
high-resolution O
MPRAGE O
image O
and O
then O
into O
standard O
Montreal O
Neurological O
Institute O
space O
, O
using O
a O
12-parameter O
affine O
transformation O
. O

An O
anatomically-defined O
region O
of O
interest O
from O
the O
Harvard-Oxford O
Subcortical O
atlas O
of O
the O
ventral O
striatum O
and O
a O
spherical O
ROI O
of O
the O
DLPFC O
( O
Montreal O
Neurological O
Institute O
coordinates O
: O
x O
= O
30 O
, O
y O
= O
36 O
, O
z O
= O
20 O
) O
were O
used O
as O
seeds O
in O
two O
separate O
analyses O
. O

The O
seeds O
were O
transformed O
into O
each O
subject O
’ O
s O
native O
space O
by O
applying O
the O
inverted O
transformation O
matrix O
of O
EPI O
to O
MPRAGE O
to O
standard O
space O
. O

In O
separate O
whole-brain O
, O
voxel-wise O
resting-state O
analyses O
, O
the O
mean O
time O
series O
across O
all O
voxels O
within O
the O
striatum O
seed O
and O
within O
the O
DLPFC O
seed O
from O
pre-processed O
images O
were O
entered O
as O
covariates O
. O

For O
IL O
markers O
that O
showed O
significant O
group O
differences O
, O
between-group O
mixed-effects O
analyses O
were O
conducted O
with O
IL O
concentrations O
as O
regressors O
to O
test O
group O
interactions O
in O
whole-brain O
voxel-wise O
regression O
of O
striatum O
and O
DLPFC O
RSFC O
( O
see O
Section O
2.6. O
for O
further O
description O
of O
statistical O
analyses O
) O
. O

All O
whole-brain O
fMRI O
statistics O
were O
corrected O
for O
multiple O
comparisons O
by O
using O
cluster-correction O
with O
voxel O
height O
threshold O
of O
Z O
> O
2.3 O
and O
cluster O
significance O
of O
P O
< O
0.05 O
. O

2.6 O
. O

Statistical O
analysis O
Student O
’ O
s O
t-tests O
and O
chi-squared O
( O
χ2 O
) O
tests O
were O
used O
to O
compare O
groups O
in O
demographic O
and O
substance O
use O
variables O
. O

A O
linear O
regression O
was O
used O
to O
test O
for O
the O
main O
effects O
of O
group O
, O
age O
, O
and O
sex O
on O
differences O
in O
IL-6 O
, O
IL-1β O
and O
IL-10 O
concentrations O
. O

In O
addition O
, O
given O
the O
non-normal O
distribution O
of O
IL-10 O
concentrations O
, O
a O
nonparametric O
Mann-Whitney O
test O
was O
conducted O
. O

Statistical O
analysis O
was O
conducted O
using O
SPSS O
24 O
( O
Armonk O
, O
NY O
: O
IBM O
Corp O
) O
. O

